Ace the Case: A 65-Year-Old Man with a History of Diabetes Mellitus, Hypertension, and Dyslipidemia

Summary and References

Summary

Randomized clinical trials have demonstrated a benefit of lowering blood pressure to <140 mm Hg systolic and <90 mm Hg diastolic in individuals with diabetes. Lowering of blood pressure with regimens based on a variety of antihypertensive agents, including ACE inhibitors, ARBs, diuretics, and calcium channel blockers, has been shown to be effective in reducing cardiovascular events. Patients with T2DM have an increased prevalence of lipid abnormalities that contribute to a higher risk of CVD. Loop diuretics are useful in the treatment of edema due to heart failure, liver disease, and kidney disease. Multiple clinical trials have demonstrated the beneficial effects of pharmacologic therapy with statins on cardiovascular outcomes in patients with and without CVD.

References

  1. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2017;40(Suppl 1):S75-87.
  2. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guidelines for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-20.
  3. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systemic review and meta-analysis. JAMA. 2015;313:603-15.
  4. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev. 2013;10:CDOO8277.
  5. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.
  6. Carlberg B, Samuelsson O, Lindholm LH, et al. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684-9.
  7. Bakris GL, Weir MR. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens. 2005;5:202-9.
  8. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646-53.
  9. Garber A, et al. AACE/ACE Consensus Statement. Endocrine Practice. Vol 24 No. 1 January 2018. https://www.aace.com/sites/all/files/diabetes-algorithm-executive-summary.pdf. Accessed 3/23/18.
  10. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90.
  11. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
  12. Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8:554-61.
  13. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.
  14. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941-50.
  15. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969-89.
  16. Singh IM, Shishehbor MH, Ansell BJ, et al. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786-98.
  17. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes (the FIELD study): randomised control trial. Lancet. 2005;366:1849-61.
  18. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120-2.
  19. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22.
  20. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.
  21. Empagliflozin [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204629s016lbl.pdf. Accessed April 17, 2018.
Back